<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136291">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063880</url>
  </required_header>
  <id_info>
    <org_study_id>41540-D</org_study_id>
    <secondary_id>2R01HD023412-21</secondary_id>
    <nct_id>NCT02063880</nct_id>
  </id_info>
  <brief_title>Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)</brief_title>
  <acronym>PUSH</acronym>
  <official_title>Urgent Versus Post-Stabilization ART in HIV-1 Infected Children With Severe Co-Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Kenya: Ethical Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Design:  Randomized clinical trial involving hospitalized HIV-1 infected children.  Children
      will be randomized to randomized to urgent (&lt;48 hours) versus early antiretroviral therapy
      (7-14 days).  This trial will be unblinded.

      Population: Hospitalized HIV-1 infected children who are antiretroviral therapy (ART) naïve
      ≤ 12 years of age.

      Sample size: 360 children will be randomized (180 per arm).

      Treatment: All infants will be treated with ART according to World Health Organization (WHO)
      and Kenyan national guidelines.

      Study duration: Enrollment into the study will occur over the course of 36-48 months and
      each infant will be routinely followed for a maximum of 6 months.

      Study site: Kenyan hospitals.

      Primary hypothesis:

      HIV-1 infected children hospitalized with severe co-infection either may be unsalvageable
      due to too far advanced immunosuppression/co-infection or may benefit from urgent ART.

      Secondary hypotheses:

      Urgent ART during an acute infection could potentially result in increased risk of immune
      reconstitution inflammatory syndrome (IRIS) or drug toxicities/interactions.

      Specific aims:

        1. To compare the 6 month all-cause mortality rate, incidence of immune reconstitution
           inflammatory syndrome (IRIS), and incidence of drug toxicity in HIV-1 infected children
           (≤ 12 years old) presenting to hospital with a serious infection randomized to urgent
           (&lt;48 hours) versus early ART (7-14 days).

        2. To determine co-factors for mortality, IRIS, and drug toxicity.  Potential cofactors
           will include: baseline weight-for-age, height-for-age, weight-for-height (Z-scores),
           CD4, HIV-1 RNA, type of co-infection, age, rate of viral load and CD4 change following
           ART, immune activation markers, pathogen and HIV-1 specific immune responses.

      Secondary aim: To determine etiologies of IRIS and to compare immune reconstitution to HIV,
      TB, EBV and CMV following ART overall and in each trial arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children will be followed and compared for 6-month mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months post-HAART initiation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution and Inflammatory Syndrome (IRIS)</measure>
    <time_frame>6 months post-HAART initiation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug toxicity</measure>
    <time_frame>6 months post-HAART initiation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Immune Reconstitution Inflammatory Syndrome</condition>
  <arm_group>
    <arm_group_label>Urgent ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initiation of HAART 7-14 days after enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urgent ART</intervention_name>
    <description>Children will be started on HAART &lt;48 hours after enrollment.</description>
    <arm_group_label>Urgent ART</arm_group_label>
    <other_name>HAART regimens recommended by WHO and Kenya MOH.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early ART</intervention_name>
    <description>Children will be started on ART after stabilization 7-14 days after enrollment.</description>
    <arm_group_label>Early ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≤ 12 years old (reported)

          -  HIV-1 positive (for example, two rapid HIV-1 antibody tests for children &gt;18 months
             and not breastfeeding, or one HIV-1 DNA/RNA test for children ≤18 months or who are
             breastfeeding)

          -  Not currently receiving antiretroviral therapy (history of pMTCT does not affect
             eligibility)

          -  Eligible to receive ART, according to current WHO guidelines

          -  Caregiver plans to reside in study catchment area for at least 6 months (reported)

          -  Caregiver provides sufficient locator information

        Exclusion Criteria:

          -  Suspected meningitis, any other central nervous system infection, or encephalitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace John Stewart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalton Wamalwa, MMed, MPH</last_name>
    <phone>+011 254 721 239 493</phone>
    <email>dalton@africaonline.co.ke</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Benki-Nugent, MS, PhD</last_name>
    <phone>206-685-9713</phone>
    <email>benki@u.washington.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kisumu District Hospital</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalton Wamalwa, MMed</last_name>
    </contact>
    <investigator>
      <last_name>Dalton Wamalwa, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JOOTRH</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalton Wamalwa, MBChB, MMed, MPH</last_name>
    </contact>
    <investigator>
      <last_name>Dalton Wamalwa, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kenyatta National Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalton Wamalwa, MBChB, MMed, MPH</last_name>
      <phone>+254 721-239-493</phone>
      <email>dalton@africaonline.co.ke</email>
    </contact>
    <investigator>
      <last_name>Dalton Wamalwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Grace John-Stewart</investigator_full_name>
    <investigator_title>Professor, Global Health</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>IRIS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
